Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Compound comparison

Sermorelin GHRH analogue ~10–20 min GHRH receptor Native GHRH 1–29 — research benchmark Tesamorelin Stabilised GHRH ~30 min Approved (HIV lipodystrophy) — visceral fat data CJC-1295 (no DAC) Modified for serum stability CJC-1295 + DAC GHRH analogue + albumin b

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Sermorelin
  • GHRH analogue
  • ~10–20 min
  • GHRH receptor
  • Native GHRH 1–29 — research benchmark
  • Tesamorelin
  • Stabilised GHRH
  • ~30 min
  • Approved (HIV lipodystrophy) — visceral fat data
  • CJC-1295 (no DAC)
  • Modified for serum stability
  • CJC-1295 + DAC
  • GHRH analogue + albumin binder
  • ~5–8 days
  • Extended half-life via albumin binding
  • Ipamorelin
  • Ghrelin mimetic
  • ~2 h
  • GHSR-1a
  • Selective — minimal cortisol/prolactin
  • Hexarelin
  • ~70 min
  • Higher potency, more cortisol
  • MK-677 (Ibutamoren)
  • Oral non-peptide ghrelin agonist
  • ~24 h
  • Once-daily oral dosing in research